AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18547955
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of r-hGH
Trial: 31477545
Drug: Fixed-combination, low-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination, low-dose, triple-pill antihypertensive therapy (amlodipine, telmisartan, chlorthalidone)
Trial: 25466805
Drug: Nebulized amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized amphotericin B (2.5 mg)
Trial: 25466805
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (0.5 mg)
Trial: 21464720
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg for 4 weeks
Trial: 21464720
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg for 4 weeks
Trial: 18769636
Drug: Various pharmacological
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pharmacological treatment modalities for TBI
Trial: 10709673
Drug: Exisulind (Sulindac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind (Sulindac sulfone) 200 mg, 300 mg, or 400 mg twice daily for six months
Trial: 10709673
Drug: Exisulind (Sulindac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind (Sulindac sulfone) at all dose levels
Trial: 7596054
Drug: Arm IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm IV: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐fluorouracil (5‐FU) 200 mg/body/day p.o. for six months
Trial: 7596054
Drug: Arm V:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm V: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Trial: 7596054
Drug: Arm I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm I: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐FU 200 mg/body/day p.o. for six months
Trial: 7596054
Drug: Arm II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm II: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Trial: 7596054
Drug: Dukes C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukes C patients in Arm II: postoperative treatment
Trial: 29949473
Drug: Heat-stable carbetocin
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable carbetocin (100 μg)
Trial: 26908570
Drug: Sensor augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor augmented pump therapy with low glucose insulin suspension
Trial: 16737798
Drug: Neurocognitive Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive Enhancement Therapy with Work Therapy (NET+WT)
Trial: 16737798
Drug: Work Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work Therapy only (WT only)
Trial: 10371095
Drug: Terfenadine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (1 mg/kg per body weight per day)
Trial: 9049968
Drug: VACPE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACPE regimen (vincristine 2 mg d1, adriamycin 25 mg/m2 d1-3, cyclophosphamide 800 mg/m2 d1, prednisone 60 mg/m2 d1-7, etoposide 120 mg/m2 d1-3)
Trial: 1910957
Drug: Intermittent cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclic etidronate (400 mg/day oral for 2 weeks, followed by 13 weeks off treatment)
Trial: 1910957
Drug: ADFR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADFR treatment (100 micrograms/day oral triiodothyronine for 7 days, followed by 400 mg/day etidronate for 2 weeks and 12 weeks off treatment)
Trial: 20977850
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg, once a day for 3-8 days
Trial: 20977850
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 0.4 ml, twice a day for 3-8 days
Trial: 15700050
Drug: Goserelin ('Zoladex')
RxNorm normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin ('Zoladex') injection using 16-gauge needle
Trial: 15700050
Drug: Leuprorelin ('Prostap')
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin ('Prostap') injection using 23-gauge needle
Trial: 15700050
Drug: Goserelin ('Zoladex')
RxNorm normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin ('Zoladex') injection
Trial: 15700050
Drug: Leuprorelin ('Prostap')
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin ('Prostap') injection
Trial: 12581262
Drug: Amantadine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (200 mg intravenous infusion)
Trial: 10479672
Drug: Fluindione plus
RxNorm normalized name: fluindione
DrugBank: Fluindione (DB13136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluindione plus aspirin (325 mg/d)
Trial: 10479672
Drug: Fluindione plus
RxNorm normalized name: fluindione
DrugBank: Fluindione (DB13136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluindione plus aspirin
Trial: 1624004
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration (2,500 U two times weekly between the 4th and 8th week of gestation)
Trial: 1624004
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration in hMG/hCG generated gestations
Trial: 1624004
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration in CC/hCG-induced pregnancies
Trial: 1624004
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration in spontaneous conceptions
Trial: 6342220
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange on six consecutive days at a mean exchange volume of 40.6 ml/kg of body weight each day
Trial: 29702502
Drug: Peri‐operative oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri‐operative oral caffeine (400 mg every 8 h for 2 days)
Trial: 25237116
Drug: CBD 75
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 750]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 75 mg/day
Trial: 22261900
Drug: brief monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: brief monthly CPR practice with voice‐activated manikins
Trial: 15979768
Drug: Single morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single morning dose (400 ml) of carbohydrate-rich drink (CL)
Trial: 15979768
Drug: Overnight fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight fasting (CC)
Trial: 15979768
Drug: Single evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single evening dose (800 ml) of carbohydrate-rich drink (LC)
Trial: 10518228
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptives with different progestogen types (desogestrel, gestodene, levonorgestrel, norgestimate) and ethinyl estradiol doses (50, 30, and 20 micrograms)
Trial: 8198904
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 300 micrograms, 1 h before and 12 h after surgery
Trial: 8198904
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine and placebo
Trial: 29655700
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination containing fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols
Trial: 24297318
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT‐based intervention)
Trial: 18657134
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of lactose
Trial: 16188753
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume packed red blood cell (PRBC) transfusions (20 ml/kg)
Trial: 16188753
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume packed red blood cell (PRBC) transfusions (15 ml/kg)
Trial: 10341394
Drug: Filtration leukocytapheresis
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtration leukocytapheresis (LCP) therapy, performed 3 times with 1 week intervals between procedures.
Trial: 27943220
Drug: Lorazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.1 mg/kg, to a maximum of 4 mg)
Trial: 26931195
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (Department of Internal Medicine) (control)
Trial: 19874051
Drug: Antibody self‐oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody self‐oriented immunoprobe on magnetic nanoparticles (MNPs)
Trial: 19874051
Drug: BA‐mediated covalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA‐mediated covalent antibody immobilization
Trial: 17497543
Drug: Health Realization
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Realization treatment
Trial: 17497543
Drug: 12-Step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Step treatment
Trial: 15018625
Drug: Botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A (Botox®) injections
Trial: 12390854
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEI)
Trial: 12390854
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker or alpha-receptor blocker (Control)
Trial: 9661601
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg sublingually)
Trial: 9661601
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (25 mg i.v. bolus)
Trial: 7631600
Drug: Coagulation monitoring
RxNorm normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulation monitoring including single daily estimation of PTF1 + 2 (target range < 0.5 nmol/L) and FII activity (15% to 35%); adjustment of heparin and phenprocoumon dosages based on PTF1 + 2 and FII measurements.
Trial: 7448680
Drug: Probucol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1 g per day)
Trial: 30915633
Drug: HCAG chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCAG chemotherapy
Trial: 30915633
Drug: FLAG chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG chemotherapy
Trial: 24629480
Drug: Brief behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief behavioral cessation treatment (1 in-person session and 3 phone calls)
Trial: 24629480
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral cessation treatment (3 in-person sessions and 5 phone calls)
Trial: 24629480
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (brief and intensive)
Trial: 17537781
Drug: Levonorgestrel (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (1.5 mg)
Trial: 11784873
Drug: Normal-calcium, low-animal-protein,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-calcium, low-animal-protein, low-salt diet (30 mmol calcium, 52 g animal protein, 50 mmol sodium chloride)
Trial: 9744372
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% applied once daily for 6 months
Trial: 2916889
Drug: Once-daily normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily normal saline irrigation
Trial: 29939302
Drug: Prebiotic (fructooligosaccharide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (fructooligosaccharide, FOS, 12 g/day)
Trial: 29939302
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 12 g/day)
Trial: 28812167
Drug: 5-aminolevulinic (5-ALA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic (5-ALA) followed by 595-nm pulsed dye laser therapy (5-ALA PDL)
Trial: 28812167
Drug: 595-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595-nm pulsed dye laser therapy alone (PDL alone)
Trial: 25842221
Drug: Injectable gentamicin
RxNorm normalized name: gentamicin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable gentamicin and oral amoxicillin for 7 days (group B)
Trial: 25842221
Drug: Injectable procaine
RxNorm normalized name: procaine Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C)
Trial: 25842221
Drug: Injectable gentamicin
RxNorm normalized name: gentamicin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D)
Trial: 15126738
Drug: Semont maneuver,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semont maneuver, Flunarizine, No treatment
Trial: 8281528
Drug: Nitrendipine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10‐20 mg twice daily)
Trial: 8733038
Drug: Lisinopril (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10‐20 mg once daily)
Trial: 3732378
Drug: Cibenzoline administered
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline administered 1 h prior to food
Trial: 3732378
Drug: Cibenzoline administered
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline administered with a standard breakfast
Trial: 3732378
Drug: Cibenzoline administered
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline administered 1 h after a standard breakfast
Trial: 31567375
Drug: T-180 mg-24
RxNorm normalized name: 2,4,5-T DIMETHYLAMMONIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-180 mg-24 h
Trial: 31567375
Drug: T-90 mg-24
RxNorm normalized name: 2,4,5-T DIMETHYLAMMONIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-90 mg-24 h
Trial: 31567375
Drug: T-90 mg-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-90 mg-12 h
Trial: 25092564
Drug: CPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT plus thalidomide (5 mg/kg)
Trial: 25092564
Drug: CPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT plus thalidomide (8 mg/kg)
Trial: 25092564
Drug: CPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT plus thalidomide (10 mg/kg)
Trial: 25092564
Drug: CPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT plus thalidomide (all doses)
Trial: 22610355
Drug: CPT‐11 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 at a fixed dose of 60 mg/m2
Trial: 20455850
Drug: Iscador (mistletoe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador (mistletoe therapy)
Trial: 18627327
Drug: Neoadjuvant cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant cisplatin-based combination chemotherapy
Trial: 10189982
Drug: Therapeutic community
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic community and community residences treatment environments
Trial: 7584934
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (delapril)
Trial: 7584934
Drug: Ca antagonist
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca antagonist
Trial: 1691882
Drug: Morphatropin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphatropin (1 ml s.c.)
Trial: 396336
Drug: Inactivated Port
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A)
Trial: 396336
Drug: Neuraminidase-specific (Heq1N2Ch)
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B)
Trial: 28013097
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Prequit Gum and In-Person Counseling
Trial: 21217614
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 10 mg plus submucous local tramadol (50 mg diluted in 1 mL saline solution)
Trial: 21217614
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 10 mg plus submucous local placebo (1 mL saline solution)
Trial: 11730183
Drug: HFA flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HFA flunisolide 170 microg, twice daily
Trial: 11730183
Drug: HFA flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HFA flunisolide 340 microg, twice daily
Trial: 11730183
Drug: CFC flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CFC flunisolide (250, 500, or 1,000 microg, twice daily)
Trial: 29405670
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% 5 mL on radial and median nerves at the elbow (dNB group)
Trial: 27930564
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (DEX) 1 μg/kg over 10 minutes, followed by 0.5 μg/kg/h continuous infusion
Trial: 19046248
Drug: Cranberry treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry treatment for 12 weeks
Trial: 15010695
Drug: 21 mg/day
RxNorm normalized name: nicotine 21 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg/day nicotine transdermal patch
Trial: 15010695
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (15 and 30 mg/70 kg)
Trial: 9550480
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies (aCL) presence in patients with giant cell arteritis
Trial: 8148435
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group) for chronic fatigue syndrome (CFS)
Trial: 2459174
Drug: Compound 48/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 48/80 at 2.4 mg/ml
Trial: 2459174
Drug: Compound 48/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 48/80 at 0.6 mg/ml
Trial: 2459174
Drug: Compound 48/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 48/80 at concentrations less than 0.6 mg/ml
Trial: 29382813
Drug: Succinylated gelatin
RxNorm normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylated gelatin (12 ml/kg)
Trial: 29382813
Drug: Hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic sodium chloride hydroxyethyl starch 40 injection
Trial: 27544892
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine Green (ICG) intravenous injection before carotid endarterectomy
Trial: 19748249
Drug: Combination treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment: Carbohydrate restriction diet for 6 weeks followed by American Heart Association diet (50-55% CHO) for an additional 6 weeks